As of Oct 24, 2024, the KRYS stock has a PE ratio of 46.41. The calculation is based on the latest EPS of $3.77 and the stock price of $174.98 per share.
Year | PE ratio | Change |
---|---|---|
2023 | 310.15 | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
In comparison to its peer stock ORMP, KRYS's PE ratio is higher.
Stock name | PE ratio | Market cap |
---|---|---|
ORMP Oramed Pharmaceuticals Inc | 4.63 | $96.21M |
KRYS Krystal Biotech Inc | 47.06 | $5.1B |
OLMA Olema Pharmaceuticals Inc | N/A | $685.48M |
OMER Omeros Corp | N/A | $246.27M |
OMGA Omega Therapeutics Inc | N/A | $79.97M |
ONCT Oncternal Therapeutics Inc | N/A | $4.41M |
ONVO Organovo Holdings Inc | N/A | $7.24M |
ORIC Oric Pharmaceuticals Inc | N/A | $594.67M |
KRYS stock has a price to earnings ratio of 46.41 as of Oct 24, 2024.
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Oct 24, 2024), Krystal Biotech's share price is $174.98. The company's earnings per share for the trailing twelve months (TTM) ending Jun 2024 is $3.77. Therefore, Krystal Biotech's PE ratio for today is 46.41. PE RATIO(46.41) = STOCK PRICE($174.98) / TTM EPS($3.77)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.